Quantcast
Home > Quotes > VTVT

vTv Therapeutics Inc. Class A Common Stock (VTVT) Quote & Summary Data

VTVT 
$1.93
*  
0.13
6.31%
Get VTVT Alerts
*Delayed - data as of Dec. 7, 2018  -  Find a broker to begin trading VTVT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3
Today's High / Low
$ 2.0337 / $ 1.89
Share Volume
93,872
50 Day Avg. Daily Volume
3,632,992
Previous Close
$ 2.06
52 Week High / Low
$ 8.40 / $ 0.65
Market Cap
82,268,313
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.45

Intraday Chart

Shares Traded

Share Volume:
93,872
50 Day Avg. Daily Volume:
3,632,992

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.11

Trading Range

The current last sale of $1.93 is 196.92% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.0337 $ 8.40
 Low: $ 1.89 $ 0.65

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. We have a powerful pipeline of clinical drug candidates, led by our programs for the treatment of mild Alzheimer's disease ("AD") and diabetes. Our drug candidate for the treatment of AD, azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts ("RAGE"), for which we have successfully completed the enrollment of both sub-studies in a Phase 3 clinical trial (the "STEADFAST Study") under a Food and Drug Administration ("FDA") agreed Special Protocol Assessment ("SPA").  ... More ...  


Risk Grade

Where does VTVT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.01
Open Date:
Dec. 7, 2018
Close Price:
$ 1.93
Close Date:
Dec. 7, 2018

Consensus Recommendation

Analyst Info